Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Jacobio Pharmaceuticals Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Jacobio Pharmaceuticals Group yıllık ortalama 16.4% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 31.7% annual. Gelirler azalıyor .

Anahtar bilgiler

16.4%

Kazanç büyüme oranı

39.7%

EPS büyüme oranı

Biotechs Sektör Büyümesi	11.0%
Gelir büyüme oranı	-38.5%
Özkaynak getirisi	-32.5%
Net Marj	-504.1%
Son Kazanç Güncellemesi	30 Jun 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Jacobio Pharmaceuticals Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SZSC:1167 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 23	81	-410	43	468
31 Mar 23	89	-391	43	457
31 Dec 22	96	-372	43	446
30 Sep 22	123	-332	46	391
30 Jun 22	150	-292	49	336
31 Mar 22	151	-297	47	308
31 Dec 21	153	-301	45	281
30 Sep 21	348	-570	52	259
30 Jun 21	544	-839	60	237
31 Mar 21	515	-1,177	57	211
31 Dec 20	486	-1,514	54	186
30 Sep 20	243	-1,298	65	171
30 Jun 20	0	-1,082	77	156
31 Mar 20	0	-753	74	147
31 Dec 19	0	-425	71	139

Kaliteli Kazançlar: 1167 şu anda kârlı değil.

Büyüyen Kar Marjı: 1167 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1167 kârlı değildir, ancak son 5 yılda zararlarını yılda 16.4% oranında azaltmıştır.

Büyüme Hızlandırma: 1167 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 1167 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 14.3% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 1167 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -32.49% ) sahiptir.

Jacobio Pharmaceuticals Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.17 loss in 1H 2022)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings released: CN¥0.49 loss per share (vs CN¥0.40 loss in FY 2021)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2022 Results on Aug 23, 2022

Recent updates

Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval from the U.S. FDA for Pan-KRAS Inhibitor JAB-23E73

Jacobio Pharmaceuticals Group Co., Ltd. Announces Board Changes

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dosing in the Phase III Clinical Trial of Glecirasib in Combination with Glecirasib

Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback Plan for 79,175,508 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.

Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer

Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 07, 2024

Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI

New minor risk - Share price stability

Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo

Executive Chairman & CEO recently bought HK$594k worth of stock

First half 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.17 loss in 1H 2022)

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 (Glecirasib) Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients

Jacobio Pharmaceuticals Group Co., Ltd. announced that it expects to receive CNY 150 million in funding from Beijing E-Town International Investment & Development Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd. Presents Clinical Results of Glecirasib in Colorectal Cancer

Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval for PARP7 Inhibitor JAB-26766 in China

Full year 2022 earnings released: CN¥0.49 loss per share (vs CN¥0.40 loss in FY 2021)

Jacobio Pharma Completes First Patient Dosage of Aurora Inhibitor JAB-2485 in U.S

Jacobio's Kras G12c Inhibitor JAB-21822 Was Granted Breakthrough Therapy Designations by China Cde

Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

Less than half of directors are independent

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China

Jacobio Pharma Completes First Patient Dosage of Cd73 Mab Jab-Bx102 in China

Jacobio Pharmaceuticals Group Co., Ltd. Announces First Patient Dosed with JAB-21822 in the Phase IIa Trial on KRAS G12C and STK11 Co-Mutation

Jacobio Pharmaceuticals Group Co., Ltd. Announces Change of Joint Company Secretary

Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2022 Results on Aug 23, 2022

Jacobio Pharma will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting

Less than half of directors are independent

Senior VP & Executive Director recently bought HK$150k worth of stock

Senior VP & Executive Director recently bought HK$336k worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

Senior VP & Executive Director recently bought HK$1.6m worth of stock

Jacobio Pharmaceuticals Group Co., Ltd. Announces Investigational New Drug Approval of Aurora A Inhibitor JAB-2485 from Food and Drug Administration of the United States

Jacobio Pharma Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of Kras G12c Inhibitor for Solid Tumor

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering $20 Million Milestone Payment

Jacobio Announces FDA Approves IND Application to Develop KRAS G12c Inhibitor

Joint Company Secretary has left the company

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin